New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2014
13:57 EDTCELGCelgene announced updated OS results from post-hoc analysis of Abraxane study
Celgene announced updated Overall Survival, OS, results from a post-hoc analysis of its phase III IMPACT, Metastatic Pancreatic Adenocarcinoma Clinical Trial, study of ABRAXANE, paclitaxel protein-bound particles for injectable suspension, in combination with gemcitabine in treatment-na´ve patients with metastatic pancreatic cancer. A poster discussion of the analysis is scheduled for Sunday, June 1st at 11:30 am CT at the 50th American Society of Clinical Oncology, ASCO, annual meeting in Chicago, Ill. The analysis also showed that the treatment effect on OS for pre-specified subgroups analyzed in the trial remained consistent across patient subgroups. Specifically, patients with Karnofsky Performance Status, KPS, KPS 90-100 had a higher median OS on ABRAXANE plus gemcitabine as compared to gemcitabine alone [median OS 9.7 months vs. 7.9 months. Patients with KPS 70-80 also maintained a benefit [median OS 7.6 months vs. 4.3 months. This updated analysis also evaluated the prognostic effects of CA19-9 and neutrophil-to-lymphocyte ratio, NLR. Both elevated CA19-9 and elevated NLR were associated with poorer survival. Further, treatment with ABRAXANE plus gemcitabine appeared to reduce the effect of CA19-9 as a poor prognostic factor, as similar overall survival was observed regardless of CA19-9 level.
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
07:09 EDTCELGCelgene price target raised to $145 from $131 at Cantor
Subscribe for More Information
January 29, 2015
12:26 EDTCELGCelgene price target raised to $135 from $115 at Piper Jaffray
Piper Jaffray raised its price target for Celgene shares to $135 following the company's Q4 results and reiterates an Overweight rating on the name. Piper believes Celgene continues to have one of the strongest mid-term growth outlooks.
07:35 EDTCELGCelgene backs FY20 adjusted EPS view to exceed $12.50
Subscribe for More Information
07:35 EDTCELGCelgene backs FY17 adjusted EPS view about $7.50
Subscribe for More Information
07:34 EDTCELGCelgene sees FY15 adjusted EPS $4.60 -$4.75, consensus $4.87
Subscribe for More Information
07:32 EDTCELGCelgene reports Q4 adjusted EPS $1.01, consensus 99c
Reports Q4 revenue $2.09B, consensus $2.08B. REVLIMID sales for Q4 increased 16% to $1,322 million and were driven by increased market share and duration of therapy.
January 28, 2015
15:38 EDTCELGNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Celgene (CELG), consensus 99c... ConocoPhillips (COP), consensus 59c... Abbott Laboratories (ABT), consensus 67c... Occidental Petroleum (OXY), consensus 68c... Colgate-Palmolive (CL), consensus 74c... Ford (F), consensus 23c... Dow Chemical (DOW), consensus 69c... Alibaba (BABA), consensus 75c... Thermo Fisher (TMO), consensus $1.94; Time Warner Cable (TWC), consensus $2.09... Phillips 66 (PSX), consensus $1.34... Alexion Pharmaceuticals (ALXN), consensus $1.29... Baxter International (BAX), consensus $1.31... Cardinal Health (CAH), consensus $1.10... Raytheon (RTN), consensus $1.08... Northrop Grumman (NOC), consensus $2.25... Viacom (VIAB), consensus $1.28... Valero Energy (VLO), consensus $1.32... Sherwin-Williams (SHW), consensus $1.38... Hershey (HSY), consensus $1.06... Mead Johnson (MJN), consensus 88c... Zimmer (ZMH), consensus $1.71... Xcel Energy (XEL), consensus 34c... Royal Caribbean (RCL), consensus 42c... Coach (COH), consensus 66c... Kate Spade (KATE), consensus 24c... Harley-Davidson (HOG), consensus 34c... Stanley Black & Decker (SWK), consensus $1.52... L-3 Communications (LLL), consensus $2.27... JetBlue (JBLU), consensus 24c.
January 23, 2015
07:21 EDTCELGCelgene receives positive CHMP opinion for ABRAXANE
Subscribe for More Information
January 21, 2015
08:36 EDTCELGCelgene price target raised to $139 from $115 at RW Baird
Baird raised its price target on Celgene to $139 from $115 following last week's guidance from the company. Baird reiterated its Outperform rating on Celgene shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use